title: The kinase inhibitors dabrafenib and trametinib affect isolated immune cell populations.
abstract: Metastatic melanoma is frequently fatal. Optimal treatment regimens require both rapid and durable disease control, likely best achieved by combining targeted agents with immunotherapeutics. In order to accomplish this, a detailed understanding of the immune consequences of the kinase inhibitors used to treat melanoma is required.
authors.affiliation: Ludwig Institute for Cancer Research; Melbourne-Austin Branch; Cancer Immuno-biology Laboratory ; Heidelberg, Australia.
authors.forename: Laura J
authors.initials: LJ
authors.lastname: Vella
authors.affiliation: Ludwig Institute for Cancer Research; Melbourne-Austin Branch; Cancer Immuno-biology Laboratory ; Heidelberg, Australia.
authors.forename: Miles C
authors.initials: MC
authors.lastname: Andrews
authors.affiliation: Ludwig Institute for Cancer Research; Melbourne-Austin Branch; Cancer Immuno-biology Laboratory ; Heidelberg, Australia.
authors.forename: Anupama
authors.initials: A
authors.lastname: Pasam
authors.affiliation: Ludwig Institute for Cancer Research; Melbourne-Austin Branch; Cancer Immuno-biology Laboratory ; Heidelberg, Australia.
authors.forename: Katherine
authors.initials: K
authors.lastname: Woods
authors.affiliation: Ludwig Institute for Cancer Research; Melbourne-Austin Branch; Cancer Immuno-biology Laboratory ; Heidelberg, Australia.
authors.forename: Andreas
authors.initials: A
authors.lastname: Behren
authors.affiliation: Ludwig Institute for Cancer Research; Melbourne-Austin Branch; Cancer Immuno-biology Laboratory ; Heidelberg, Australia.
authors.forename: Jonathan S
authors.initials: JS
authors.lastname: Cebon
keywords: BRAF; MEK; T-lymphocytes; dendritic cells; melanoma